Eli Lilly ramps up AI ambitions with this $2.8 billion deal
- 2 hours ago
- 1 min read
BARRON’S — As the healthcare industry scrambles to integrate artificial intelligence, Eli Lilly is signaling it was already ahead of the curve.
InSilico, a self-professed “AI-driven biotech company,” unveiled a deal with the drugmaker Sunday that could be valued at up to $2.75 billion. Under the terms of the arrangement, Lilly will receive exclusive worldwide rights to manufacture and sell oral treatments discovered using InSilico’s Pharma.AI model.
Read the full story | BARRON’S
